Identity
- Security key
- 21400
- Ticker
- SCLX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2022-11-11
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- SCLX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $48,527,727.6
- Shares outstanding (class)
- 8,491,267
- Shares outstanding (weighted)
- 7,033,004
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 34
- Location
- PALO ALTO, CA
- Homepage
- https://www.scilexholding.com
- Description
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.